Parallels between pathogens and gluten peptides in celiac sprue

PLoS Pathogens

Volumn 4, Issue 2, 2008, Pages

  Bethune, Michael T ^a   Khosla, Chaitan ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON ANTIBODY; GLUTEN; INFLIXIMAB; PEPTIDE DERIVATIVE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; IMMUNOTOXIN; PEPTIDE;

AMINO ACID SEQUENCE; BACTERIAL COLONIZATION; CELIAC DISEASE; CELLULAR IMMUNITY; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL TRACT; HELICOBACTER PYLORI; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNITY; IMMUNOTOXICITY; INFECTION SENSITIVITY; INNATE IMMUNITY; INTESTINE EPITHELIUM; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROORGANISM DETECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN DEGRADATION; REVIEW; SMALL INTESTINE ABSORPTION; STOMACH; T LYMPHOCYTE; ADAPTATION; ANIMAL; DISEASE MODEL; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; INTESTINE MUCOSA; LYMPHOID TISSUE; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY; SMALL INTESTINE;

ANIMALIA;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; BASE SEQUENCE; CELIAC DISEASE; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; GLUTEN; HUMANS; IMMUNITY, NATURAL; IMMUNOTOXINS; INTESTINAL MUCOSA; INTESTINE, SMALL; LYMPHOID TISSUE; MOLECULAR SEQUENCE DATA; PEPTIDES;

EID: 40349098215     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.0040034     Document Type: Review

References (211)

1. Woolhouse ME, Gowtage-Sequeria S (2005) Host range and emerging and reemerging pathogens. Emerg Infect Dis 11: 1842-1847.
2. Falkow S (1997) What is a pathogen? ASM News 63: 359-365.
3. Casadevall A, Pirofski LA (2002) What is a pathogen? Ann Med 34: 2-4.
4. Casadevall A, Pirofski LA (1999) Host-pathogen interactions: redefining the basic concepts of virulence and pathogenicity. Infect Immun 67: 3703-3713.
5. Falkow S (2006) Is persistent bacterial infection good for your health? Cell 124: 699-702.
6. Lukens R, editor (2005) Stedman's medical dictionary, 28th edition. Baltimore: Lippincott Williams & Wilkins.
7. Harden VA (1992) Koch's postulates and the etiology of AIDS: an historical perspective. Hist Philos Life Sci 14: 249-269.
8. Walker L, Levine H, Jucker M (2006) Koch's postulates and infectious proteins. Acta Neuropathol (Berl) 112: 1-4.
9. Prusiner SB (1982) Novel proteinaceous infectious particles cause scrapie. Science 216: 136-144.
10. Watts JC, Balachandran A, Westaway D (2006) The expanding universe of prion diseases. PLoS Pathog 2: e26. doi:10.1371/journal.ppat.0020026
11. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, et al. (2002) Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 36: 1206-1213.
12. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, et al. (2004) Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 126: 840-848.
13. Greenstein RJ (2003) Is Crohn's disease caused by a mycobacterium? Comparisons with leprosy, tuberculosis, and Johne's disease. Lancet Infect Dis 3: 507-514.
14. Marshall BJ, Warren JR (1984) Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1: 1311-1315.
15. Fox JG, Wang TC (2007) Inflammation, atrophy, and gastric cancer. J Clin Invest 117: 60-69.
16. Woodman CB, Collins SI, Young LS (2007) The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 7: 11-22.
17. zur Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2: 342-350.
18. Mackowiak PA (1987) Microbial oncogenesis. Am J Med 82: 79-97.
19. Pagano JS, Blaser M, Buendia MA, Damania B, Khalili K, et al. (2004) Infectious agents and cancer: criteria for a causal relation. Semin Cancer Biol 14: 453-471.
20. Haverkos HW (2004) Viruses, chemicals and co-carcinogenesis. Oncogene 23: 6492-6499.
21. Anderson DM, editor (2003) Dorland's illustrated medical dictionary, 30th edition. Philadelphia: Saunders.
22. Dicke WK, Weijers HA, Van De Kamer JH (1953) Coeliac disease. II. The presence in wheat of a factor having a deleterious effect in cases of coeliac disease. Acta Paediatr 42: 34-42.
23. Hausch F, Shan L, Santiago NA, Gray GM, Khosla C (2002) Intestinal digestive resistance of immunodominant gliadin peptides. Am J Physiol Gastrointest Liver Physiol 283: G996-G1003.
24. Shan L, Molberg O, Parrot I, Hausch F, Filiz F, et al. (2002) Structural basis for gluten intolerance in celiac sprue. Science 297: 2275-2279.
25. Sollid LM (2002) Coeliac disease: dissecting a complex inflammatory disorder. Nat Rev Immunol 2: 647-655.
26. Alaedini A, Green PH (2005) Narrative review: celiac disease: understanding a complex autoimmune disorder. Ann Intern Med 142: 289-298.
27. Green PH, Jabri B (2006) Celiac disease. Annu Rev Med 57: 207-221.
28. Corrao G, Corazza GR, Bagnardi V, Brusco G, Ciacci C, et al. (2001) Mortality in patients with coeliac disease and their relatives: a cohort study. Lancet 358: 356-361.
29. Catassi C, Fabiani E, Corrao G, Barbato M, De Renzo A, et al. (2002) Risk of non-Hodgkin lymphoma in celiac disease. JAMA 287: 1413-1419.
30. See J, Murray JA (2006) Gluten-free diet: the medical and nutrition management of celiac disease. Nutr Clin Pract 21: 1-15.
31. Segal S, Hill AV (2003) Genetic susceptibility to infectious disease. Trends Microbiol 11: 445-448.
32. Kusters JG, van Vliet AH, Kuipers EJ (2006) Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 19: 449-490.
33. Johnston SD, Watson RG, McMillan SA, Sloan J, Love AH (1998) Coeliac disease detected by screening is not silent-simply unrecognized. QJM 91: 853-860.
34. Louka AS, Sollid LM (2003) HLA in coeliac disease: unravelling the complex genetics of a complex disorder. Tissue Antigens 61: 105-117.
35. Smecuol E, Maurino E, Vazquez H, Pedreira S, Niveloni S, et al. (1996) Gynaecological and obstetric disorders in coeliac disease: frequent clinical onset during pregnancy or the puerperium. Eur J Gastroenterol Hepatol 8: 63-89.
36. Forsberg G, Fahlgren A, Horstedt P, Hammarstrom S, Hernell O, et al. (2004) Presence of bacteria and innate immunity of intestinal epithelium in childhood celiac disease. Am J Gastroenterol 99: 894-904.
37. Murray JA, Watson T, Clearman B, Mitros F (2004) Effect of a gluten-free diet on gastrointestinal symptoms in celiac disease. Am J Clin Nutr 79: 669-673.
38. Martinsen TC, Bergh K, Waldum HL (2005) Gastric juice: a barrier against infectious diseases. Basic Clin Pharmacol Toxicol 96: 94-102.
39. Martinsen TC, Taylor DM, Johnsen R, Waldum HL (2002) Gastric acidity protects mice against prion infection? Scand J Gastroenterol 37: 497-500.
40. Marshall BJ, Barrett LJ, Prakash C, McCallum RW, Guerrant RL (1990) Urea protects Helicobacter (Campylobacter) pylori from the bactericidal effect of acid. Gastroenterology 99: 697-702.
41. Clyne M, Dolan B, Reeves EP (2007) Bacterial factors that mediate colonization of the stomach and virulence of Helicobacter pylori. FEMS Microbiol Lett 268: 135-143.
42. Young GM, Amid D, Miller VL (1996) A bifunctional urease enhances survival of pathogenic Yersinia enterocolitica and Morganella morganii at low pH. J Bacteriol 178: 6487-6495.
43. Lin J, Lee IS, Frey J, Slonczewski JL, Foster JW (1995) Comparative analysis of extreme acid survival in Salmonella typhimurium, Shigella flexneri, and Escherichia coli. J Bacteriol 177: 4097-4104.
44. Erickson RH, Kim YS (1990) Digestion and absorption of dietary protein. Annu Rev Med 41: 133-139.
45. Gray GM (1991) Dietary protein processing: intraluminal and enterocyte surface events. In: Frizzell RA, editor. Handbook of physiology. New York: Oxford University Press. pp. 411-420.
46. Piper JL, Gray GM, Khosla C (2004) Effect of prolyl endopeptidase on digestive-resistant gliadin peptides in vivo. J Pharmacol Exp Ther 311: 213-219.
47. Wieser H (1995) The precipitating factor in coeliac disease. Baillieres Clin Gastroenterol 9: 191-207.
48. Wieser H (2007) Chemistry of gluten proteins. Food Microbiol 24: 115-119.
49. Shewry PR, Halford NG, Belton PS, Tatham AS (2002) The structure and properties of gluten: an elastic protein from wheat grain. Philos Trans R Soc Lond B Biol Sci 357: 133-142.
50. Michelitsch MD, Weissman JS (2000) A census of glutamine/asparagine-rich regions: implications for their conserved function and the prediction of novel prions. Proc Natl Acad Sci U S A 97: 11910-11915.
51. Tuite MF, Cox BS (2003) Propagation of yeast prions. Nat Rev Mol Cell Biol 4: 878-890.
52. Millhauser GL (2007) Copper and the prion protein: methods, structures, function, and disease. Annu Rev Phys Chem 58: 299-320.
53. Ter-Avanesyan MD, Dagkesamanskaya AR, Kushnirov VV, Smirnov VN (1994) The SUP35 omnipotent suppressor gene is involved in the maintenance of the non-Mendelian determinant [psi+] in the yeast Saccharomyces cerevisiae. Genetics 137: 671-676.
54. Li L, Lindquist S (2000) Creating a protein-based element of inheritance. Science 287: 661-664.
55. Flechsig E, Shmerling D, Hegyi I, Raeber AJ, Fischer M, et al. (2000) Prion protein devoid of the octapeptide repeat region restores susceptibility to scrapie in PrP knockout mice. Neuron 27: 399-408.
56. Tank EM, Harris DA, Desai AA, True HL (2007) Prion protein repeat expansion results in increased aggregation and reveals phenotypic variability. Mol Cell Biol 27: 5445-5455.
57. Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A, et al. (1993) Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci U S A 90: 10962-10966.
58. McKinley MP, Bolton DC, Prusiner SB (1983) A protease-resistant protein is a structural component of the scrapie prion. Cell 35: 57-62.
59. van de Wal Y, Kooy YM, van Veelen P, Vader W, August SA, et al. (1999) Glutenin is involved in the gluten-driven mucosal T cell response. Eur J Immunol 29: 3133-3139.
60. Vader W, Kooy Y, Van Veelen P, De Ru A, Harris D, et al. (2002) The gluten response in children with celiac disease is directed toward multiple gliadin and glutenin peptides. Gastroenterology 122: 1729-1737.
61. Molberg O, Solheim Flaete N, Jensen T, Lundin KE, Arentz-Hansen H, et al. (2003) Intestinal T-cell responses to high-molecular-weight glutenins in celiac disease. Gastroenterology 125: 337-344.
62. Dewar DH, Amato M, Ellis HJ, Pollock EL, Gonzalez-Cinca N, et al. (2006) The toxicity of high molecular weight glutenin subunits of wheat to patients with coeliac disease. Eur J Gastroenterol Hepatol 18: 483-491.
63. Shan L, Qiao SW, Arentz-Hansen H, Molberg O, Gray GM, et al. (2005) Identification and analysis of multivalent proteolytically resistant peptides from gluten: implications for celiac sprue. J Proteome Res 4: 1732-1741.
64. Lopez S, Arias CF (2004) Multistep entry of rotavirus into cells: a Versaillesque dance. Trends Microbiol 12: 271-278.
65. Nava P, Lopez S, Arias CF, Islas S, Gonzalez-Mariscal L (2004) The rotavirus surface protein VP8 modulates the gate and fence function of tight junctions in epithelial cells. J Cell Sci 117: 5509-5519.
66. Schneeberger EE, Lynch RD (2004) The tight junction: a multifunctional complex. Am J Physiol Cell Physiol 286: C1213-C1228.
67. Perez-Moreno M, Jamora C, Fuchs E (2003) Sticky business: orchestrating cellular signals at adherens junctions. Cell 112: 535-548.
68. Vogelmann R, Amieva MR, Falkow S, Nelson WJ (2004) Breaking into the epithelial apical-junctional complex-news from pathogen hackers. Curr Opin Cell Biol 16: 86-93.
69. Sousa S, Lecuit M, Cossart P (2005) Microbial strategies to target, cross or disrupt epithelia. Curr Opin Cell Biol 17: 489-498.
70. Wu Z, Nybom P, Magnusson KE (2000) Distinct effects of Vibrio cholerae haemagglutinin/protease on the structure and localization of the tight junction-associated proteins occludin and ZO-1. Cell Microbiol 2: 11-17.
71. Wu S, Lim KC, Huang J, Saidi RF, Sears CL (1998) Bacteroides fragilis enterotoxin cleaves the zonula adherens protein, E-cadherin. Proc Natl Acad Sci U S A 95: 14979-14984.
72. Amieva MR, Vogelmann R, Covacci A, Tompkins LS, Nelson WJ, et al. (2003) Disruption of the epithelial apical-junctional complex by Helicobacter pylori CagA. Science 300: 1430-1434.
73. Dean P, Kenny B (2004) Intestinal barrier dysfunction by enteropathogenic Escherichia coli is mediated by two effector molecules and a bacterial surface protein. Mol Microbiol 54: 665-675.
74. Lecuit M, Vandormael-Pournin S, Lefort J, Huerre M, Gounon P, et al. (2001) A transgenic model for listeriosis: role of internalin in crossing the intestinal barrier. Science 292: 1722-1725.
75. Pentecost M, Otto G, Theriot JA, Amieva MR (2006) Listeria monocytogenes invades the epithelial junctions at sites of cell extrusion. PLoS Pathog 2: e3. doi: 10.1371/journal.ppat.0020003
76. Cossart P, Sansonetti PJ (2004) Bacterial invasion: the paradigms of enteroinvasive pathogens. Science 304: 242-248.
77. Okamoto M, Furuoka H, Horiuchi M, Noguchi T, Hagiwara K, et al. (2003) Experimental transmission of abnormal prion protein (PrPsc) in the small intestinal epithelial cells of neonatal mice. Vet Pathol 40: 723-727.
78. Heppner FL, Christ AD, Klein MA, Prinz M, Fried M, et al. (2001) Transepithelial prion transport by M cells. Nat Med 7: 976-977.
79. Moss SF, Attia L, Scholes JV, Walters JR, Holt PR (1996) Increased small intestinal apoptosis in coeliac disease. Gut 39: 811-817.
80. Ciccocioppo R, Di Sabatino A, Parroni R, Muzi P, D'Alo S, et al. (2001) Increased enterocyte apoptosis and Fas-Fas ligand system in celiac disease. Am J Clin Pathol 115: 494-503.
81. Schulzke JD, Bentzel CJ, Schulzke I, Riecken EO, Fromm M (1998) Epithelial tight junction structure in the jejunum of children with acute and treated celiac sprue. Pediatr Res 43: 435-441.
82. Ciccocioppo R, Finamore A, Ara C, Di Sabatino A, Mengheri E, et al. (2006) Altered expression, localization, and phosphorylation of epithelial junctional proteins in celiac disease. Am J Clin Pathol 125: 502-511.
83. Bjarnason I, Peters TJ, Veall N (1983) A persistent defect in intestinal permeability in coeliac disease demonstrated by a 51Cr-labelled EDTA absorption test. Lancet 1: 323-325.
84. Bjarnason I, Peters TJ (1984) In vitro determination of small intestinal permeability: demonstration of a persistent defect in patients with coeliac disease. Gut 25: 145-150.
85. Bjarnason I, Marsh MN, Price A, Levi AJ, Peters TJ (1985) Intestinal permeability in patients with coeliac disease and dermatitis herpetiformis. Gut 26: 1214-1219.
86. Greco L, D'Adamo G, Truscelli A, Parrilli G, Mayer M, et al. (1991) Intestinal permeability after single dose gluten challenge in coeliac disease. Arch Dis Child 66: 870-872.
87. Smecuol E, Bai JC, Vazquez H, Kogan Z, Cabanne A, et al. (1997) Gastrointestinal permeability in celiac disease. Gastroenterology 112: 1129-1136.
88. Zimmer KP, Poremba C, Weber P, Ciclitira PJ, Harms E (1995) Translocation of gliadin into HLA-DR antigen containing lysosomes in coeliac disease enterocytes. Gut 36: 703-709.
89. Matysiak-Budnik T, Candalh C, Dugave C, Namane A, Cellier C, et al. (2003) Alterations of the intestinal transport and processing of gliadin peptides in celiac disease. Gastroenterology 125: 696-707.
90. Matysiak-Budnik T, Candalh C, Cellier C, Dugave C, Namane A, et al. (2005) Limited efficiency of prolyl-endopeptidase in the detoxification of gliadin peptides in celiac disease. Gastroenterology 129: 786-796.
91. Nilsen EM, Lundin KE, Krajci P, Scott H, Sollid LM, et al. (1995) Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon gamma. Gut 37: 766-776.
92. Nilsen EM, Jahnsen FL, Lundin KE, Johansen FE, Fausa O, et al. (1998) Gluten induces an intestinal cytokine response strongly dominated by interferon gamma in patients with celiac disease. Gastroenterology 115: 551-563.
93. Troncone R, Gianfrani C, Mazzarella G, Greco L, Guardiola J, et al. (1998) Majority of gliadin-specific T-cell clones from celiac small intestinal mucosa produce interferon-gamma and interleukin-4. Dig Dis Sci 43: 156-161.
94. Clayburgh DR, Shen L, Turner JR (2004) A porous defense: the leaky epithelial barrier in intestinal disease. Lab Invest 84: 282-291.
95. Bruewer M, Samarin S, Nusrat A (2006) Inflammatory bowel disease and the apical junctional complex. Ann N Y Acad Sci 1072: 242-252.
96. Bruewer M, Utech M, Ivanov AI, Hopkins AM, Parkos CA, et al. (2005) Interferon-gamma induces internalization of epithelial tight junction proteins via a macropinocytosis-like process. FASEB J 19: 923-933.
97. Utech M, Ivanov AI, Samarin SN, Bruewer M, Turner JR, et al. (2005) Mechanism of IFN-gamma-induced endocytosis of tight junction proteins: myosin II-dependent vacuolarization of the apical plasma membrane. Mol Biol Cell 16: 5040-5052.
98. Madara JL, Stafford J (1989) Interferon-gamma directly affects barrier function of cultured intestinal epithelial monolayers. J Clin Invest 83: 724-727.
99. Bruewer M, Luegering A, Kucharzik T, Parkos CA, Madara JL, et al. (2003) Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol 171: 6164-6172.
100. Rodriguez P, Heyman M, Candalh C, Blaton MA, Bouchaud C (1995) Tumour necrosis factor-alpha induces morphological and functional alterations of intestinal HT29 cl.19A cell monolayers. Cytokine 7: 441-448.
101. Terpend K, Boisgerault F, Blaton MA, Desjeux JF, Heyman M (1998) Protein transport and processing by human HT29-19A intestinal cells: effect of interferon gamma. Gut 42: 538-545.
102. Friis S, Dabelsteen E, Sjostrom H, Noren O, Jarnum S (1992) Gliadin uptake in human enterocytes. Differences between coeliac patients in remission and control individuals. Gut 33: 1487-1492.
103. Mayer M, Greco L, Troncone R, Auricchio S, Marsh MN (1991) Compliance of adolescents with coeliac disease with a gluten free diet. Gut 32: 881-885.
104. Ciacci C, Cirillo M, Cavallaro R, Mazzacca G (2002) Long-term follow-up of celiac adults on gluten-free diet: prevalence and correlates of intestinal damage. Digestion 66: 178-185.
105. Pietzak MM (2005) Follow-up of patients with celiac disease: achieving compliance with treatment. Gastroenterology 128: S135-S141.
106. Cornell HJ, Macrae FA, Melny J, Pizzey CJ, Cook F, et al. (2005) Enzyme therapy for management of coeliac disease. Scand J Gastroenterol 40: 1304-1312.
107. Matysiak-Budnik T, Terpend K, Alain S, Sanson le Pors MJ, Desjeux JF, et al. (1998) Helicobacter pylori alters exogenous antigen absorption and processing in a digestive tract epithelial cell line model. Infect Immun 66: 5785-5791.
108. Dokladny K, Moseley PL, Ma TY (2006) Physiologically relevant increase in temperature causes an increase in intestinal epithelial tight junction permeability. Am J Physiol Gastrointest Liver Physiol 290: G204-G212.
109. Jelinkova L, Tuckova L, Cinova J, Flegelova Z, Tlaskalova-Hogenova H (2004) Gliadin stimulates human monocytes to production of IL-8 and TNF-alpha through a mechanism involving NF-kappaB. FEBS Lett 571: 81-85.
110. Sander GR, Cummins AG, Henshall T, Powell BC (2005) Rapid disruption of intestinal barrier function by gliadin involves altered expression of apical junctional proteins. FEBS Lett 579: 4851-4855.
111. Drago S, El Asmar R, Di Pierro M, Grazia Clemente M, Tripathi A, et al. (2006) Gliadin, zonulin and gut permeability: Effects on celiac and nonceliac intestinal mucosa and intestinal cell lines. Scand J Gastroenterol 41: 408-419.
112. Gardner ML (1988) Gastrointestinal absorption of intact proteins. Annu Rev Nutr 8: 329-350.
113. Heyman M (2001) Symposium on 'dietary influences on mucosal immunity'. How dietary antigens access the mucosal immune system. Proc Nutr Soc 60: 419-426.
114. Husby S, Foged N, Host A, Svehag SE (1987) Passage of dietary antigens into the blood of children with coeliac disease. Quantification and size distribution of absorbed antigens. Gut 28: 1062-1072.
115. Peng HJ, Turner MW, Strobel S (1990) The generation of a 'tolerogen' after the ingestion of ovalbumin is time-dependent and unrelated to serum levels of immunoreactive antigen. Clin Exp Immunol 81: 510-515.
116. Ziv E, Bendayan M (2000) Intestinal absorption of peptides through the enterocytes. Microsc Res Tech 49: 346-352.
117. Chirdo FG, Rumbo M, Anon MC, Fossati CA (1998) Presence of high levels of non-degraded gliadin in breast milk from healthy mothers. Scand J Gastroenterol 33: 1186-1192.
118. Raki M, Tollefsen S, Molberg O, Lundin KE, Sollid LM, et al. (2006) A unique dendritic cell subset accumulates in the celiac lesion and efficiently activates gluten-reactive T cells. Gastroenterology 131: 428-438.
119. Collin P, Maki M, Keyrilainen O, Hallstrom O, Reunala T, et al. (1992) Selective IgA deficiency and coeliac disease. Scand J Gastroenterol 27: 367-371.
120. Kelly J, Weir DG, Feighery C (1988) Differential expression of HLA-D gene products in the normal and coeliac small bowel. Tissue Antigens 31: 151-160.
121. Raki M, Schjetne KW, Stamnaes J, Molberg O, Jahnsen FL, et al. (2007) Surface expression of transglutaminase 2 by dendritic cells and its potential role for uptake and presentation of gluten peptides to T cells. Scand J Immunol 65: 213-220.
122. Rescigno M, Urbano M, Valzasina B, Francolini M, Rotta G, et al. (2001) Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol 2: 361-367.
123. Bukrinskaya AG (2004) HIV-1 assembly and maturation. Arch Virol 149: 1067-1082.
124. Ochman H, Lawrence JG, Groisman EA (2000) Lateral gene transfer and the nature of bacterial innovation. Nature 405: 299-304.
125. Sjostrom H, Lundin KE, Molberg O, Korner R, McAdam SN, et al. (1998) Identification of a gliadin T-cell epitope in coeliac disease: general importance of gliadin deamidation for intestinal T-cell recognition. Scand J Immunol 48: 111-115.
126. Molberg O, McAdam SN, Korner R, Quarsten H, Kristiansen C, et al. (1998) Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat Med 4: 713-717.
127. Arentz-Hansen H, Korner R, Molberg O, Quarsten H, Vader W, et al. (2000) The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. J Exp Med 191: 603-612.
128. Bruce SE, Bjarnason I, Peters TJ (1985) Human jejunal transglutaminase: demonstration of activity, enzyme kinetics and substrate specificity with special relation to gliadin and coeliac disease. Clin Sci (Lond) 68: 573-579.
129. Esposito C, Paparo F, Caputo I, Porta R, Salvati VM, et al. (2003) Expression and enzymatic activity of small intestinal tissue transglutaminase in celiac disease. Am J Gastroenterol 98: 1813-1820.
130. Biagi F, Campanella J, Laforenza U, Gastaldi G, Tritto S, et al. (2006) Transglutaminase 2 in the enterocytes is coeliac specific and gluten dependent. Dig Liver Dis 38: 652-658.
131. Lorand L, Graham RM (2003) Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 4: 140-156.
132. Fleckenstein B, Molberg O, Qiao SW, Schmid DG, von der Mulbe F, et al. (2002) Gliadin T cell epitope selection by tissue transglutaminase in celiac disease. Role of enzyme specificity and pH influence on the transamidation versus deamidation process. J Biol Chem 277: 34109-34116.
133. Vader LW, de Ru A, van der Wal Y, Kooy YM, Benckhuijsen W, et al. (2002) Specificity of tissue transglutaminase explains cereal toxicity in celiac disease. J Exp Med 195: 643-649.
134. Quarsten H, Molberg O, Fugger L, McAdam SN, Sollid LM (1999) HLA binding and T cell recognition of a tissue transglutaminase-modified gliadin epitope. Eur J Immunol 29: 2506-2514.
135. Kim CY, Quarsten H, Bergseng E, Khosla C, Sollid LM (2004) Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease. Proc Natl Acad Sci USA 101: 4175-4179.
136. Arentz-Hansen EH, McAdam SN, Molberg O, Kristiansen C, Sollid LM (2000) Production of a panel of recombinant gliadins for the characterisation of T cell reactivity in coeliac disease. Gut 46: 46-51.
137. Arentz-Hansen H, McAdam SN, Molberg O, Fleckenstein B, Lundin KE, et al. (2002) Celiac lesion T cells recognize epitopes that cluster in regions of gliadins rich in proline residues. Gastroenterology 123: 803-809.
138. Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, et al. (1997) Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 3: 797-801.
139. Fleckenstein B, Qiao SW, Larsen MR, Jung G, Roepstorff P, et al. (2004) Molecular characterization of covalent complexes between tissue transglutaminase and gliadin peptides. J Biol Chem 279: 17607-17616.
140. Sollid LM, Molberg O, McAdam S, Lundin KE (1997) Autoantibodies in coeliac disease: tissue transglutaminase-guilt by association? Gut 41: 851-852.
141. Londei M, Ciacci C, Ricciardelli I, Vacca L, Quaratino S, et al. (2005) Gliadin as a stimulator of innate responses in celiac disease. Mol Immunol 42: 913-918.
142. Jabri B, Kasarda DD, Green PH (2005) Innate and adaptive immunity: the yin and yang of celiac disease. Immunol Rev 206: 219-231.
143. Gianfrani C, Auricchio S, Troncone R (2005) Adaptive and innate immune responses in celiac disease. Immunol Lett 99: 141-145.
144. Maiuri L, Ciacci C, Ricciardelli I, Vacca L, Raia V, et al. (2003) Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease. Lancet 362: 30-37.
145. Hue S, Mention JJ, Monteiro RC, Zhang S, Cellier C, et al. (2004) A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 21: 367-377.
146. Di Sabatino A, Ciccocioppo R, Cupelli F, Cinque B, Millimaggi D, et al. (2006) Epithelium derived interleukin 15 regulates intraepithelial lymphocyte Th1 cytokine production, cytotoxicity, and survival in coeliac disease. Gut 55: 469-477.
147. Jabri B, de Serre NP, Cellier C, Evans K, Gache C, et al. (2000) Selective expansion of intraepithelial lymphocytes expressing the HLA-E-specific natural killer receptor CD94 in celiac disease. Gastroenterology 118: 867-879.
148. Roberts AI, Lee L, Schwarz E, Groh V, Spies T, et al. (2001) NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. J Immunol 167: 5527-5530.
149. Meresse B, Chen Z, Ciszewski C, Tretiakova M, Bhagat G, et al. (2004) Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 21: 357-366.
150. Maiuri L, Ciacci C, Auricchio S, Brown V, Quaratino S, et al. (2000) Interleukin 15 mediates epithelial changes in celiac disease. Gastroenterology 119: 996-1006.
151. Mention JJ, Ben Ahmed M, Begue B, Barbe U, Verkarre V, et al. (2003) Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology 125: 730-745.
152. Maiuri L, Ciacci C, Ricciardelli I, Vacca L, Raia V, et al. (2005) Unexpected role of surface transglutaminase type II in celiac disease. Gastroenterology 129: 1400-1413.
153. Monteleone G, Pender SL, Alstead E, Hauer AC, Lionetti P, et al. (2001) Role of interferon alpha in promoting T helper cell type 1 responses in the small intestine in coeliac disease. Gut 48: 425-429.
154. Bardella MT, Marino R, Meroni PL (1999) Celiac disease during interferon treatment. Ann Intern Med 131: 157-158.
155. Monteleone G, Pender SL, Wathen NC, MacDonald TT (2001) Interferon-alpha drives T cell-mediated immunopathology in the intestine. Eur J Immunol 31: 2247-2255.
156. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G (2006) Inflammation and cancer: how hot is the link? Biochem Pharmacol 72: 1605-1621.
157. Vogelmann R, Amieva MR (2007) The role of bacterial pathogens in cancer. Curr Opin Microbiol 10: 76-81.
158. Cellier C, Delabesse E, Helmer C, Patey N, Matuchansky C, et al. (2000) Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group. Lancet 356: 203-208.
159. Marti T, Molberg O, Li Q, Gray GM, Khosla C, et al. (2005) Prolyl endopeptidase-mediated destruction of T cell epitopes in whole gluten: chemical and immunological characterization. J Pharmacol Exp Ther 312: 19-26.
160. Mitea C, Havenaar R, Drijfhout JW, Edens L, Dekking L, et al. (2008) Efficient degradation of gluten by a prolyl endoprotease in a gastrointestinal model: implications for coeliac disease. Gut 57: 25-32.
161. Xia J, Sollid LM, Khosla C (2005) Equilibrium and kinetic analysis of the unusual binding behavior of a highly immunogenic gluten peptide to HLA-DQ2. Biochemistry 44: 4442-4449.
162. Siegel M, Bethune MT, Gass J, Ehren J, Xia J, et al. (2006) Rational design of combination enzyme therapy for celiac sprue. Chem Biol 13: 649-658.
163. March JB (2003) High antigliadin IgG titers in laboratory rabbits fed a wheat-containing diet: a model for celiac disease? Dig Dis Sci 48: 608-610.
164. Batt RM, Carter MW, McLean L (1984) Morphological and biochemical studies of a naturally occurring enteropathy in the Irish setter dog: a comparison with coeliac disease in man. Res Vet Sci 37: 339-346.
165. Batt RM, McLean L, Carter MW (1987) Sequential morphologic and biochemical studies of naturally occurring wheat-sensitive enteropathy in Irish setter dogs. Dig Dis Sci 32: 184-194.
166. Hall EJ, Batt RM (1992) Dietary modulation of gluten sensitivity in a naturally occurring enteropathy of Irish setter dogs. Gut 33: 198-205.
167. Hall EJ, Batt RM (1991) Abnormal permeability precedes the development of a gluten sensitive enteropathy in Irish setter dogs. Gut 32: 749-753.
168. Hall EJ, Carter SD, Barnes A, Batt RM (1992) Immune responses to dietary antigens in gluten-sensitive enteropathy of Irish setters. Res Vet Sci 53: 293-299.
169. Polvi A, Garden OA, Elwood CM, Sorensen SH, Batt RM, et al. (1997) Canine major histocompatibility complex genes DQA and DQB in Irish setter dogs. Tissue Antigens 49: 236-243.
170. Polvi A, Garden OA, Houlston RS, Maki M, Batt RM, et al. (1998) Genetic susceptibility to gluten sensitive enteropathy in Irish setter dogs is not linked to the major histocompatibility complex. Tissue Antigens 52: 543-549.
171. Harris RL, Streett JW, Morrow D, Lord PF (1984) Villus atrophy and malabsorption in a rhesus monkey. Lab Anim Sci 34: 610-613.
172. Wagner JD, Jerome CP, Adams MR (1988) Gluten-sensitive enteropathy in a cynomolgus monkey. Lab Anim Sci 38: 592-594.
173. Marietta E, Black K, Camilleri M, Krause P, Rogers RS 3rd, et al. (2004) A new model for dermatitis herpetiformis that uses HLA-DQ8 transgenic NOD mice. J Clin Invest 114: 1090-1097.
174. Sollid LM, Khosla C (2005) Future therapeutic options for celiac disease. Nat Clin Pract Gastroenterol Hepatol 2: 140-147.
175. Spaenij-Dekking L, Kooy-Winkelaar Y, van Veelen P, Drijfhout JW, Jonker H, et al. (2005) Natural variation in toxicity of wheat: potential for selection of nontoxic varieties for celiac disease patients. Gastroenterology 129: 797-806.
176. De Angelis M, Rizzello CG, Fasano A, Clemente MG, De Simone C, et al. (2006) VSL#3 probiotic preparation has the capacity to hydrolyze gliadin polypeptides responsible for Celiac Sprue. Biochim Biophys Acta 1762: 80-93.
177. Gianfrani C, Siciliano RA, Facchiano AM, Camarca A, Mazzeo MF, et al. (2007) Transamidation of wheat flour inhibits the response to gliadin of intestinal T cells in celiac disease. Gastroenterology 133: 780-789.
178. Bruce G, Woodley JF, Swan CH (1984) Breakdown of gliadin peptides by intestinal brush borders from coeliac patients. Gut 25: 919-924.
179. Stepniak D, Koning F (2006) Enzymatic gluten detoxification: the proof of the pudding is in the eating! Trends Biotechnol 24: 433-434.
180. Cerf-Bensussan N, Matysiak-Budnik T, Cellier C, Heyman M (2007) Oral proteases: a new approach to managing coeliac disease. Gut 56: 157-160.
181. Gass J, Khosla C (2007) Prolyl endopeptidases. Cell Mol Life Sci 64: 345-355.
182. Stepniak D, Spaenij-Dekking L, Mitea C, Moester M, de Ru A, et al. (2006) Highly efficient gluten degradation with a newly identified prolyl endoprotease: implications for celiac disease. Am J Physiol Gastrointest Liver Physiol 291: G621-G629.
183. Gass J, Bethune MT, Siegel M, Spencer A, Khosla C (2007) Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue. Gastroenterology 133: 472-480.
184. Bethune MT, Strop P, Tang Y, Sollid LM, Khosla C (2006) Heterologous expression, purification, refolding, and structural-functional characterization of EP-B2, a self-activating barley cysteine endoprotease. Chem Biol 13: 637-647.
185. Gass J, Vora H, Bethune MT, Gray GM, Khosla C (2006) Effect of barley endoprotease EP-B2 on gluten digestion in the intact rat. J Pharmacol Exp Ther 318: 1178-1186.
186. Suenaert P, Bulteel V, Lemmens L, Noman M, Geypens B, et al. (2002) Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol 97: 2000-2004.
187. Clemente MG, De Virgiliis S, Kang JS, Macatagney R, Musu MP, et al. (2003) Early effects of gliadin on enterocyte intracellular signalling involved in intestinal barrier function. Gut 52: 218-223.
188. Watts T, Berti I, Sapone A, Gerarduzzi T, Not T, et al. (2005) Role of the intestinal tight junction modulator zonulin in the pathogenesis of type I diabetes in BB diabetic-prone rats. Proc Natl Acad Sci U S A 102: 2916-2921.
189. Paterson BM, Lammers KM, Arrieta MC, Fasano A, Meddings JB (2007) The
190. Molberg O, McAdam S, Lundin KE, Kristiansen C, Arentz-Hansen H, et al. (2001) T cells from celiac disease lesions recognize gliadin epitopes deamidated in situ by endogenous tissue transglutaminase. Eur J Immunol 31: 1317-1323.
191. Siegel M, Khosla C (2007) Transglutaminase 2 inhibitors and their therapeutic role in disease states. Pharmacol Ther 115: 232-245.
192. Hausch F, Halttunen T, Maki M, Khosla C (2003) Design, synthesis, and evaluation of gluten peptide analogs as selective inhibitors of human tissue transglutaminase. Chem Biol 10: 225-231.
193. Choi K, Siegel M, Piper JL, Yuan L, Cho E, et al. (2005) Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2. Chem Biol 12: 469-475.
194. Watts RE, Siegel M, Khosla C (2006) Structure-activity relationship analysis of the selective inhibition of transglutaminase 2 by dihydroisoxazoles. J Med Chem 49: 7493-7501.
195. Strnad P, Siegel M, Toivola DM, Choi K, Kosek JC, et al. (2006) Pharmacologic transglutaminase inhibition attenuates drug-primed liver hypertrophy but not Mallory body formation. FEBS Lett 580: 2351-2357.
196. Shimba N, Yokoyama K, Suzuki E (2002) NMR-based screening method for transglutaminases: rapid analysis of their substrate specificities and reaction rates. J Agric Food Chem 50: 1330-1334.
197. Yokoyama K, Nio N, Kikuchi Y (2004) Properties and applications of microbial transglutaminase. Appl Microbiol Biotechnol 64: 447-454.
198. Skovbjerg H, Noren O, Anthonsen D, Moller J, Sjostrom H (2002) Gliadin is a good substrate of several transglutaminases: possible implication in the pathogenesis of coeliac disease. Scand J Gastroenterol 37: 812-817.
199. Senger S, Luongo D, Maurano F, Mazzeo MF, Siciliano RA, et al. (2003) Intranasal administration of a recombinant alpha-gliadin down-regulates the immune response to wheat gliadin in DQ8 transgenic mice. Immunol Lett 88: 127-134.
200. Biagi F, Ellis HJ, Parnell ND, Shidrawi RG, Thomas PD, et al. (1999) A non-toxic analogue of a coeliac-activating gliadin peptide: a basis for immunomodulation? Aliment Pharmacol Ther 13: 945-950.
201. Xia J, Siegel M, Bergseng E, Sollid LM, Khosla C (2006) Inhibition of HLADQ2-mediated antigen presentation by analogues of a high affinity 33-residue peptide from alpha2-gliadin. J Am Chem Soc 128: 1859-1867.
202. Ogasawara K, Hamerman JA, Ehrlich LR, Bour-Jordan H, Santamaria P, et al. (2004) NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity 20: 757-767.
203. Przemioslo RT, Lundin KE, Sollid LM, Nelufer J, Ciclitira PJ (1995) Histological changes in small bowel mucosa induced by gliadin sensitive T lymphocytes can be blocked by anti-interferon gamma antibody. Gut 36: 874-879.
204. Chaudhary R, Ghosh S (2005) Infliximab in refractory coeliac disease. Eur J Gastroenterol Hepatol 17: 603-604.
205. Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, et al. (1999) Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 116: 22-28.
206. Nakamura K, Honda K, Mizutani T, Akiho H, Harada N (2006) Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules. World J Gastroenterol 12: 4628-4635.
207. Gillett HR, Arnott ID, McIntyre M, Campbell S, Dahele A, et al. (2002) Successful infliximab treatment for steroid-refractory celiac disease: a case report. Gastroenterology 122: 800-805.
208. Turner SM, Moorghen M, Probert CS (2005) Refractory coeliac disease: remission with infliximab and immunomodulators. Eur J Gastroenterol Hepatol 17: 667-669.
209. Brown NF, Wickham ME, Coombes BK, Finlay BB (2006) Crossing the line: selection and evolution of virulence traits. PLoS Pathog 2: e42. doi:10.1371/journal.ppat.0020042
210. Sturgess R, Day P, Ellis HJ, Lundin KE, Gjertsen HA, et al. (1994) Wheat peptide challenge in coeliac disease. Lancet 343: 758-761.
211. Fraser JS, Engel W, Ellis HJ, Moodie SJ, Pollock EL, et al. (2003) Coeliac disease: in vivo toxicity of the putative immunodominant epitope. Gut 52: 1698-1702.